← All trials
NCT05254808
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 6, 2021
- Primary completion
- Feb 14, 2022
- Completion date
- Feb 14, 2022
- First posted
- Feb 24, 2022
- Last posted
- Mar 15, 2022
- Enrollment
- 13
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Utrecht UniversityLead sponsor
- Utrecht UniversityOverall official - principal investigator
- Utrecht UniversitySponsor investigator
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
- Utrecht UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.